testosterone propionate half life

Local reactions Frequent: pain, localized edema, erythema, and induration of the skin pigmentation at the injection site; extravasation can cause inflammation testosterone propionate half life and necrosis of the subcutaneous tissue.

Other rare: asthenia, fever, dehydration, weakness.

Overdose symptoms, relief measures in overdose
Symptoms: inhibition of bone marrow, peripheral neuropathy, inflammation and ulceration of the mucous membranes.
Treatment: symptomatic. Antidote paclitaxel is not known.

Interaction with other drugs
Cisplatin reduces total clearance of paclitaxel by 20%, so the combined chemotherapy of paclitaxel should be entered prior to cisplatin. More severe myelosuppression observed when paclitaxel is administered after cisplatin. When combined chemotherapy (cisplatin and paclitaxel) risk of developing renal failure higher than with cisplatin alone.

Co-administration with cimetidine, ranitidine, dexamethasone or diphenhydramine did not affect the relationship paclitaxel plasma proteins. Since the elimination of doxorubicin and its active metabolites can be reduced while reducing the time interval between doses of paclitaxel and doxorubicin, paclitaxel must be administered 24 hours after doxorubicin.

Information on potential interactions of paclitaxel with inhibitors and inducers of isoenzymes of cytochrome P-450 (in particular isoenzyme CYP3A4) is limited, therefore caution is required while the use of inhibitors (eg, erythromycin, fluoxetine, gemfibrozil) or inducers (eg, rifampin, carbamazepine, phenytoin, phenobarbital) isoenzymes of cytochrome P450.

Mikrosomalnogo oxidation inhibitors (including ketoconazole, cimetidine, verapamil, diazepam, quinidine, cyclosporin, etc.) Inhibit the metabolism of paclitaxel. However, it is known that while taking ketoconazole and paclitaxel, the latter does not slow down elimination, so both drugs can be used without dose adjustment.

With simultaneous use of paclitaxel and ritonavir or nelfinavir (but not indinavir) significantly reduced systemic clearance of paclitaxel. Insufficient information about the interaction of paclitaxel and other protease inhibitors with concomitant use.

Polyoxyethylated castor oil, testosterone propionate half life which is part of paclitaxel can cause extraction di- (2-hexyl) phthalate (DEGP) of plasticized polyvinyl chloride container wherein the degree of leaching DEGP increases with increasing solution concentration and time. Therefore, in the preparation, storage and administration of the drug, Paclitaxel Ebewe equipment must be used, which contains no parts of PVC.

paclitaxel-Ebewe should be administered under the supervision of a qualified physician with experience in anti-cancer chemotherapeutic agents. Paclitaxel-Ebewe may be applied as a monotherapy, or in combination with other anticancer agents. The dose and regimen of medication is chosen individually.

When working with the drug Paclitaxel-Ebewe must be careful. Dilute the drug should be under aseptic conditions in a dedicated room. This should deal with trained staff. It is necessary to take all measures to prevent contact with skin paclitaxel solution and mucous membranes, in particular the use of protective clothing (gown, cap, mask, goggles and disposable gloves). Inhalation of vapors or spray solutions of paclitaxel were reported occurrence of shortness of breath, chest pain, burning sensation in the throat, nausea. After contact with paclitaxel in the skin or mucous membranes must be thoroughly washed with soap and water or (eye) with plenty of water.

The drug should not be frozen, as this may pellet form therein. This precipitate was dissolved by heating usually vial at room temperature (25 ° C). If the solution in previously frozen vial is cloudy or there is present an insoluble precipitate, the drug can not be used and a bottle should be discarded. The prepared solution for infusion does not need protection from light.

In case of severe hypersensitivity reactions, infusion of the drug Paclitaxel-Ebewe should be discontinued immediately and symptomatic treatment start. Enter the drug should not be repeated.

During treatment should regularly monitor the blood count, blood pressure, heart rate and breathing (especially at the beginning of infusion), electrocardiogram.

In cases of violations of testosterone propionate half life atrioventricular conduction, after repeated administration necessary to carry out continuous monitoring of the electrocardiogram. Paclitaxel-Ebewe If used in combination with cisplatin, Paclitaxel should be administered first-Ebewe and then cisplatin.

Patients during treatment with Paclitaxel Ebewe, and for at least 3 months after completion of therapy should use reliable methods of contraception.

Since the safety and efficacy of paclitaxel-Ebewe in children has not been established, it is not recommended to use the drug in this age group of patients.

Information on the possible impact of Paclitaxel Ebewe-on ability to drive vehicles, machinery
because of the likelihood of side effects such as headache, dizziness, sleepiness, should refrain from activities potentially hazardous activities that require high concentration and psychomotor speed reactions.

Special precautions for the destruction of unused drugs
Remains of the drug and all the tools and materials that were used to prepare the solution for infusion and administration of Paclitaxel-Ebewe, must be disposed of in accordance with standard hospital waste disposal procedure cytotoxic substances, taking into account existing regulatory destroy dangerous acts waste. anabolic steroids online pharmacy

testosterone cypionate for sale

online anabolic steroids